ID   DYR1A_HUMAN             Reviewed;         763 AA.
AC   Q13627; O60769; Q92582; Q92810; Q9UNM5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 1A;
DE            EC=2.7.12.1 {ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443, ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188};
DE   AltName: Full=Dual specificity YAK1-related kinase;
DE   AltName: Full=HP86;
DE   AltName: Full=Protein kinase minibrain homolog;
DE            Short=MNBH;
DE            Short=hMNB;
GN   Name=DYRK1A; Synonyms=DYRK, MNB, MNBH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), VARIANT PRO-679, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=8975710; DOI=10.1006/geno.1996.0636;
RA   Song W.J., Sternberg L.R., Kasten-Sportes C., van Keuren M.L.,
RA   Chung S.H., Slack A.C., Miller D.E., Glover T.W., Chiang P.W., Lou L.,
RA   Kurnit D.W.;
RT   "Isolation of human and murine homologues of the Drosophila minibrain
RT   gene: human homologue maps to 21q22.2 in the Down syndrome 'critical
RT   region'.";
RL   Genomics 38:331-339(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), TISSUE SPECIFICITY, AND
RP   POSSIBLE INVOLVEMENT IN DOWN SYNDROME.
RX   PubMed=8872470; DOI=10.1093/hmg/5.9.1305;
RA   Guimera J., Casas C., Pucharcos C., Solans A., Domenech A.,
RA   Planas A.M., Ashley J., Lovett M., Estivill X., Pritchard M.A.;
RT   "A human homologue of Drosophila minibrain (MNB) is expressed in the
RT   neuronal regions affected in Down syndrome and maps to the critical
RT   region.";
RL   Hum. Mol. Genet. 5:1305-1310(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND DEVELOPMENTAL STAGE.
RC   TISSUE=Fetal brain;
RX   PubMed=8769099; DOI=10.1006/bbrc.1996.1135;
RA   Shindoh N., Kudoh J., Maeda H., Yamaki A., Minoshima S., Shimizu Y.,
RA   Shimizu N.;
RT   "Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene
RT   from 'the Down syndrome critical region' of chromosome 21.";
RL   Biochem. Biophys. Res. Commun. 225:92-99(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Promyelocytic leukemia;
RX   PubMed=9037601; DOI=10.1101/gr.7.1.47;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O.,
RA   Hattori M., Sakaki Y., Eki T., Murakami Y., Saito T., Ichikawa H.,
RA   Ohki M.;
RT   "Gene identification in 1.6-Mb region of the Down syndrome region on
RT   chromosome 21.";
RL   Genome Res. 7:47-58(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, POSSIBLE
RP   INVOLVEMENT IN DOWN SYNDROME, VARIANTS PHE-415 AND HIS-681, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=10329007; DOI=10.1006/geno.1999.5775;
RA   Guimera J., Casas C., Estivill X., Pritchard M.A.;
RT   "Human minibrain homologue (MNBH/DYRK1): characterization, alternative
RT   splicing, differential tissue expression, and overexpression in Down
RT   syndrome.";
RL   Genomics 57:407-418(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 234-380.
RC   TISSUE=Fetal brain;
RX   PubMed=9503011; DOI=10.1006/geno.1997.5146;
RA   Dahmane N., Ait-Ghezala G., Gosset P., Chamoun Z.,
RA   Dufresne-Zacharia M.-C., Lopes C., Rabatel N., Gassanova-Maugenre S.,
RA   Chettouh Z., Abramowski V., Fayet E., Yaspo M.-L., Korn B.,
RA   Blouin J.-L., Lehrach H., Poustka A., Antonarakis S.E., Sinet P.-M.,
RA   Creau N., Delabar J.-M.;
RT   "Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21
RT   involved in Down syndrome.";
RL   Genomics 48:12-23(1998).
RN   [7]
RP   INTERACTION WITH RANBP9, AND ENZYME REGULATION.
RX   PubMed=14500717; DOI=10.1074/jbc.M307556200;
RA   Zou Y., Lim S., Lee K., Deng X., Friedman E.;
RT   "Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial
RT   cell migration and is negatively regulated by the Met adaptor Ran-
RT   binding protein M.";
RL   J. Biol. Chem. 278:49573-49581(2003).
RN   [8]
RP   INTERACTION WITH WDR68.
RX   PubMed=14593110; DOI=10.1074/jbc.M301769200;
RA   Skurat A.V., Dietrich A.D.;
RT   "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family
RT   protein kinases.";
RL   J. Biol. Chem. 279:2490-2498(2004).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-748 AND SER-758, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   POLY-HISTIDINE REPEATS.
RX   PubMed=19266028; DOI=10.1371/journal.pgen.1000397;
RA   Salichs E., Ledda A., Mularoni L., Alba M.M., de la Luna S.;
RT   "Genome-wide analysis of histidine repeats reveals their role in the
RT   localization of human proteins to the nuclear speckles compartment.";
RL   PLoS Genet. 5:E1000397-E1000397(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-145, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20167603; DOI=10.1074/jbc.M110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [14]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=21294719; DOI=10.1111/j.1399-0004.2010.01544.x;
RA   van Bon B.W., Hoischen A., Hehir-Kwa J., de Brouwer A.P.,
RA   Ruivenkamp C., Gijsbers A.C., Marcelis C.L., de Leeuw N.,
RA   Veltman J.A., Brunner H.G., de Vries B.B.;
RT   "Intragenic deletion in DYRK1A leads to mental retardation and primary
RT   microcephaly.";
RL   Clin. Genet. 79:296-299(2011).
RN   [15]
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=21127067; DOI=10.1074/jbc.M110.157909;
RA   Papadopoulos C., Arato K., Lilienthal E., Zerweck J., Schutkowski M.,
RA   Chatain N., Muller-Newen G., Becker W., de la Luna S.;
RT   "Splice variants of the dual specificity tyrosine phosphorylation-
RT   regulated kinase 4 (DYRK4) differ in their subcellular localization
RT   and catalytic activity.";
RL   J. Biol. Chem. 286:5494-5505(2011).
RN   [16]
RP   INTERACTION WITH SRSF6.
RX   PubMed=22767602; DOI=10.1074/jbc.M112.355412;
RA   Yin X., Jin N., Gu J., Shi J., Zhou J., Gong C.X., Iqbal K.,
RA   Grundke-Iqbal I., Liu F.;
RT   "Dual-specificity tyrosine phosphorylation-regulated kinase 1A
RT   (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted
RT   Tau exon 10 inclusion.";
RL   J. Biol. Chem. 287:30497-30506(2012).
RN   [17]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B.,
RA   Phelps I.G., Carvill G., Kumar A., Lee C., Ankenman K., Munson J.,
RA   Hiatt J.B., Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P.,
RA   Martin B.K., Borenstein E., Nickerson D.A., Mefford H.C., Doherty D.,
RA   Akey J.M., Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [18]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23415227; DOI=10.1016/j.cell.2013.01.033;
RA   Wippich F., Bodenmiller B., Trajkovska M.G., Wanka S., Aebersold R.,
RA   Pelkmans L.;
RT   "Dual specificity kinase DYRK3 couples stress granule
RT   condensation/dissolution to mTORC1 signaling.";
RL   Cell 152:791-805(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND TYR-145, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   INTERACTION WITH HADV5 E1A (MICROBIAL INFECTION).
RX   PubMed=23864635; DOI=10.1128/JVI.00786-13;
RA   Cohen M.J., Yousef A.F., Massimi P., Fonseca G.J., Todorovic B.,
RA   Pelka P., Turnell A.S., Banks L., Mymryk J.S.;
RT   "Dissection of the C-terminal region of E1A redefines the roles of
RT   CtBP and other cellular targets in oncogenic transformation.";
RL   J. Virol. 87:10348-10355(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-529, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 126-490 IN COMPLEXES WITH
RP   THE SYNTHETIC INHIBITORS HARMINE AND INDY, CATALYTIC ACTIVITY, AND
RP   FUNCTION.
RX   PubMed=20981014; DOI=10.1038/ncomms1090;
RA   Ogawa Y., Nonaka Y., Goto T., Ohnishi E., Hiramatsu T., Kii I.,
RA   Yoshida M., Ikura T., Onogi H., Shibuya H., Hosoya T., Ito N.,
RA   Hagiwara M.;
RT   "Development of a novel selective inhibitor of the Down syndrome-
RT   related kinase Dyrk1A.";
RL   Nat. Commun. 1:86-86(2010).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 128-485, CATALYTIC ACTIVITY,
RP   AND ENZYME REGULATION.
RX   PubMed=22998443; DOI=10.1021/jm301034u;
RA   Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M.,
RA   Burgy G., Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F.,
RA   Oberholzer A.E., Pearl L.H., Carreaux F., Bazureau J.P., Knapp S.,
RA   Meijer L.;
RT   "Selectivity, cocrystal structures, and neuroprotective properties of
RT   leucettines, a family of protein kinase inhibitors derived from the
RT   marine sponge alkaloid leucettamine B.";
RL   J. Med. Chem. 55:9312-9330(2012).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 127-485 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=24239188; DOI=10.1016/j.bmcl.2013.10.055;
RA   Anderson K., Chen Y., Chen Z., Dominique R., Glenn K., He Y.,
RA   Janson C., Luk K.C., Lukacs C., Polonskaia A., Qiao Q., Railkar A.,
RA   Rossman P., Sun H., Xiang Q., Vilenchik M., Wovkulich P., Zhang X.;
RT   "Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel
RT   series of DYRK1B and DYRK1A inhibitors.";
RL   Bioorg. Med. Chem. Lett. 23:6610-6615(2013).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 127-485 IN COMPLEXES WITH
RP   PEPTIDE SUBSTRATE AND INHIBITOR DJM2005, CATALYTIC ACTIVITY, FUNCTION,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-188 AND TYR-321,
RP   PHOSPHORYLATION AT TYR-111; TYR-140; TYR-159; TYR-177; SER-310;
RP   TYR-319; TYR-321; THR-402 AND TYR-449, ACTIVE SITE, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=23665168; DOI=10.1016/j.str.2013.03.012;
RA   Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P.,
RA   Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S.,
RA   Elkins J.M.;
RT   "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of
RT   kinase activation and substrate recognition.";
RL   Structure 21:986-996(2013).
RN   [26]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-679.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual-specificity kinase which possesses both
CC       serine/threonine and tyrosine kinase activities. May play a role
CC       in a signaling pathway regulating nuclear functions of cell
CC       proliferation. Modulates alternative splicing by phosphorylating
CC       the splice factor SRSF6 (By similarity). Exhibits a substrate
CC       preference for proline at position P+1 and arginine at position P-
CC       3. Has pro-survival function and negatively regulates the
CC       apoptotic process. Promotes cell survival upon genotoxic stress
CC       through phosphorylation of SIRT1. This in turn inhibits TP53
CC       activity and apoptosis (By similarity).
CC       {ECO:0000250|UniProtKB:Q61214, ECO:0000250|UniProtKB:Q9NR20,
CC       ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:21127067,
CC       ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:8769099}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443,
CC       ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188}.
CC   -!- ENZYME REGULATION: Inhibited by RANBP9 (PubMed:14500717).
CC       Inhibited by harmine, leucettamine B and leucettine L41
CC       (PubMed:22998443). {ECO:0000269|PubMed:14500717,
CC       ECO:0000269|PubMed:22998443}.
CC   -!- SUBUNIT: Interacts RAD54L2/ARIP4 (By similarity). Interacts with
CC       CRY2 (By similarity). Interacts with RANBP9 (PubMed:14500717).
CC       Interacts with WDR68 (PubMed:14593110). Interacts with SRSF6
CC       (PubMed:22767602). Interacts with SIRT1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61214, ECO:0000269|PubMed:14500717,
CC       ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:22767602,
CC       ECO:0000269|PubMed:24239188}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human adenovirus 5
CC       E1A protein (PubMed:23864635). {ECO:0000269|PubMed:23864635}.
CC   -!- INTERACTION:
CC       P61962:DCAF7; NbExp=5; IntAct=EBI-1053596, EBI-359808;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-1053596, EBI-741037;
CC       P06400:RB1; NbExp=3; IntAct=EBI-1053596, EBI-491274;
CC       P28749:RBL1; NbExp=3; IntAct=EBI-1053596, EBI-971402;
CC       Q12815:TROAP; NbExp=3; IntAct=EBI-1053596, EBI-2349743;
CC       P31946:YWHAB; NbExp=3; IntAct=EBI-1053621, EBI-359815;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:23415227}. Nucleus speckle
CC       {ECO:0000250|UniProtKB:Q61214}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=Q13627-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q13627-2; Sequence=VSP_004917;
CC       Name=2;
CC         IsoId=Q13627-3; Sequence=VSP_004918, VSP_004919;
CC       Name=3;
CC         IsoId=Q13627-4; Sequence=VSP_004920, VSP_004921;
CC       Name=4;
CC         IsoId=Q13627-5; Sequence=VSP_004922, VSP_004923;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highest levels in skeletal muscle,
CC       testis, fetal lung and fetal kidney. {ECO:0000269|PubMed:10329007,
CC       ECO:0000269|PubMed:8769099, ECO:0000269|PubMed:8872470,
CC       ECO:0000269|PubMed:8975710}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the developing central nervous
CC       system. Overexpressed 1.5-fold in fetal Down syndrome brain.
CC       {ECO:0000269|PubMed:8769099}.
CC   -!- DOMAIN: The polyhistidine repeats act as targeting signals to
CC       nuclear speckles. {ECO:0000269|PubMed:19266028}.
CC   -!- PTM: Autophosphorylated on numerous tyrosine residues. Can also
CC       autophosphorylate on serine and threonine residues (in vitro).
CC       {ECO:0000269|PubMed:23665168}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 7 (MRD7)
CC       [MIM:614104]: A disease characterized by primary microcephaly,
CC       severe mental retardation without speech, anxious autistic
CC       behavior, and dysmorphic features, including bitemporal narrowing,
CC       deep-set eyes, large simple ears, and a pointed nasal tip. Mental
CC       retardation is characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:21294719, ECO:0000269|PubMed:23160955}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MNB/DYRK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DYRK1AID43234ch21q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U58496; AAC50939.1; -; mRNA.
DR   EMBL; U52373; AAB18639.1; -; mRNA.
DR   EMBL; D85759; BAA12866.1; -; mRNA.
DR   EMBL; D86550; BAA13110.1; -; mRNA.
DR   EMBL; AF108830; AAD31169.1; -; mRNA.
DR   EMBL; AJ001870; CAA05059.1; -; mRNA.
DR   CCDS; CCDS13653.1; -. [Q13627-2]
DR   CCDS; CCDS13654.1; -. [Q13627-3]
DR   CCDS; CCDS42925.1; -. [Q13627-1]
DR   CCDS; CCDS42926.1; -. [Q13627-5]
DR   PIR; JC4898; JC4898.
DR   RefSeq; NP_001334650.1; NM_001347721.1. [Q13627-2]
DR   RefSeq; NP_001334651.1; NM_001347722.1. [Q13627-2]
DR   RefSeq; NP_001387.2; NM_001396.4. [Q13627-1]
DR   RefSeq; NP_567824.1; NM_101395.2. [Q13627-5]
DR   RefSeq; NP_569120.1; NM_130436.2. [Q13627-2]
DR   RefSeq; NP_569122.1; NM_130438.2. [Q13627-3]
DR   RefSeq; XP_006724039.1; XM_006723976.3. [Q13627-1]
DR   RefSeq; XP_006724040.1; XM_006723977.3. [Q13627-1]
DR   RefSeq; XP_006724041.1; XM_006723978.3. [Q13627-1]
DR   RefSeq; XP_011527785.1; XM_011529483.2. [Q13627-1]
DR   RefSeq; XP_016883773.1; XM_017028284.1. [Q13627-2]
DR   UniGene; Hs.368240; -.
DR   PDB; 2VX3; X-ray; 2.40 A; A/B/C/D=127-485.
DR   PDB; 2WO6; X-ray; 2.50 A; A/B=127-485.
DR   PDB; 3ANQ; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 3ANR; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 4AZE; X-ray; 3.15 A; A/B/C=128-485.
DR   PDB; 4MQ1; X-ray; 2.35 A; A/B/C/D=127-485.
DR   PDB; 4MQ2; X-ray; 2.80 A; A/B/C/D=127-485.
DR   PDB; 4NCT; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 4YLJ; X-ray; 2.58 A; A/B/C/D=127-485.
DR   PDB; 4YLK; X-ray; 1.40 A; A=127-485.
DR   PDB; 4YLL; X-ray; 1.40 A; A=127-485.
DR   PDB; 4YU2; X-ray; 2.90 A; A/B/C/D=127-485.
DR   PDB; 5A3X; X-ray; 2.26 A; A/B/C/D=126-490.
DR   PDB; 5A4E; X-ray; 2.68 A; A/B/C/D=126-490.
DR   PDB; 5A4L; X-ray; 2.73 A; A/B/C/D=126-490.
DR   PDB; 5A4Q; X-ray; 2.37 A; A/B/C/D=126-490.
DR   PDB; 5A4T; X-ray; 2.15 A; A/B/C/D=126-490.
DR   PDB; 5A54; X-ray; 2.63 A; A/B/C/D=126-490.
DR   PDB; 5AIK; X-ray; 2.70 A; A/B/C/D=128-485.
DR   PDBsum; 2VX3; -.
DR   PDBsum; 2WO6; -.
DR   PDBsum; 3ANQ; -.
DR   PDBsum; 3ANR; -.
DR   PDBsum; 4AZE; -.
DR   PDBsum; 4MQ1; -.
DR   PDBsum; 4MQ2; -.
DR   PDBsum; 4NCT; -.
DR   PDBsum; 4YLJ; -.
DR   PDBsum; 4YLK; -.
DR   PDBsum; 4YLL; -.
DR   PDBsum; 4YU2; -.
DR   PDBsum; 5A3X; -.
DR   PDBsum; 5A4E; -.
DR   PDBsum; 5A4L; -.
DR   PDBsum; 5A4Q; -.
DR   PDBsum; 5A4T; -.
DR   PDBsum; 5A54; -.
DR   PDBsum; 5AIK; -.
DR   ProteinModelPortal; Q13627; -.
DR   SMR; Q13627; -.
DR   BioGrid; 108192; 72.
DR   DIP; DIP-39750N; -.
DR   IntAct; Q13627; 35.
DR   MINT; MINT-1205413; -.
DR   STRING; 9606.ENSP00000381932; -.
DR   BindingDB; Q13627; -.
DR   ChEMBL; CHEMBL2292; -.
DR   DrugBank; DB07608; N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide.
DR   GuidetoPHARMACOLOGY; 2009; -.
DR   iPTMnet; Q13627; -.
DR   PhosphoSitePlus; Q13627; -.
DR   BioMuta; DYRK1A; -.
DR   DMDM; 3219996; -.
DR   EPD; Q13627; -.
DR   MaxQB; Q13627; -.
DR   PaxDb; Q13627; -.
DR   PeptideAtlas; Q13627; -.
DR   PRIDE; Q13627; -.
DR   DNASU; 1859; -.
DR   Ensembl; ENST00000338785; ENSP00000342690; ENSG00000157540. [Q13627-5]
DR   Ensembl; ENST00000339659; ENSP00000340373; ENSG00000157540. [Q13627-2]
DR   Ensembl; ENST00000398956; ENSP00000381929; ENSG00000157540. [Q13627-3]
DR   Ensembl; ENST00000398960; ENSP00000381932; ENSG00000157540. [Q13627-1]
DR   GeneID; 1859; -.
DR   KEGG; hsa:1859; -.
DR   UCSC; uc002ywi.4; human. [Q13627-1]
DR   CTD; 1859; -.
DR   DisGeNET; 1859; -.
DR   GeneCards; DYRK1A; -.
DR   HGNC; HGNC:3091; DYRK1A.
DR   HPA; HPA015323; -.
DR   HPA; HPA015810; -.
DR   MalaCards; DYRK1A; -.
DR   MIM; 600855; gene.
DR   MIM; 614104; phenotype.
DR   neXtProt; NX_Q13627; -.
DR   OpenTargets; ENSG00000157540; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   PharmGKB; PA27545; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   eggNOG; ENOG410XPET; LUCA.
DR   GeneTree; ENSGT00760000119032; -.
DR   HOGENOM; HOG000220863; -.
DR   HOVERGEN; HBG051425; -.
DR   InParanoid; Q13627; -.
DR   KO; K08825; -.
DR   OMA; RQGIDRE; -.
DR   OrthoDB; EOG091G03J7; -.
DR   PhylomeDB; Q13627; -.
DR   TreeFam; TF314624; -.
DR   BRENDA; 2.7.12.1; 2681.
DR   Reactome; R-HSA-1538133; G0 and Early G1.
DR   SignaLink; Q13627; -.
DR   SIGNOR; Q13627; -.
DR   ChiTaRS; DYRK1A; human.
DR   EvolutionaryTrace; Q13627; -.
DR   GeneWiki; DYRK1A; -.
DR   GenomeRNAi; 1859; -.
DR   PRO; PR:Q13627; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000157540; -.
DR   CleanEx; HS_DYRK1A; -.
DR   ExpressionAtlas; Q13627; baseline and differential.
DR   Genevisible; Q13627; HS.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; TAS:Reactome.
DR   GO; GO:0043621; F:protein self-association; ISS:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; ISS:BHF-UCL.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; ISS:BHF-UCL.
DR   GO; GO:0048025; P:negative regulation of mRNA splicing, via spliceosome; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0090312; P:positive regulation of protein deacetylation; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0000381; P:regulation of alternative mRNA splicing, via spliceosome; IEA:Ensembl.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR028318; DYRK1A/MNB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24058:SF68; PTHR24058:SF68; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Host-virus interaction; Kinase; Mental retardation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN         1    763       Dual specificity tyrosine-
FT                                phosphorylation-regulated kinase 1A.
FT                                /FTId=PRO_0000085931.
FT   DOMAIN      159    479       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     165    173       ATP. {ECO:0000305}.
FT   NP_BIND     238    241       ATP. {ECO:0000305}.
FT   MOTIF       117    134       Bipartite nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    509    515       Poly-Ser.
FT   COMPBIAS    599    602       Poly-His.
FT   COMPBIAS    607    619       Poly-His.
FT   COMPBIAS    656    672       Ser/Thr-rich.
FT   COMPBIAS    664    671       Poly-Ser.
FT   ACT_SITE    287    287       Proton acceptor.
FT                                {ECO:0000305|PubMed:23665168}.
FT   BINDING     188    188       ATP. {ECO:0000305}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     111    111       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     140    140       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     145    145       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     159    159       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     177    177       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     219    219       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:Q63470}.
FT   MOD_RES     310    310       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     319    319       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     321    321       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     402    402       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     449    449       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MOD_RES     529    529       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     538    538       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61214}.
FT   MOD_RES     748    748       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     758    758       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   VAR_SEQ      70     78       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:8769099,
FT                                ECO:0000303|PubMed:9037601}.
FT                                /FTId=VSP_004917.
FT   VAR_SEQ     516    540       GGSSGTSNSGRARSDPTHQHRHSGG -> VEQHWMPGAFRM
FT                                TVSFTLEVHDVPV (in isoform 3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_004920.
FT   VAR_SEQ     516    529       GGSSGTSNSGRARS -> GASAISCSSWLVRH (in
FT                                isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_004918.
FT   VAR_SEQ     530    763       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_004919.
FT   VAR_SEQ     541    763       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_004921.
FT   VAR_SEQ     559    584       RQQFPAPLGWSGTEAPTQVTVETHPV -> SSHVVHLLVSP
FT                                AILRWSSTGCQVPLE (in isoform 4).
FT                                {ECO:0000303|PubMed:10329007}.
FT                                /FTId=VSP_004922.
FT   VAR_SEQ     585    763       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:10329007}.
FT                                /FTId=VSP_004923.
FT   VARIANT     415    415       Y -> F. {ECO:0000269|PubMed:10329007}.
FT                                /FTId=VAR_009395.
FT   VARIANT     679    679       A -> P (in dbSNP:rs55720916).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:8975710}.
FT                                /FTId=VAR_040453.
FT   VARIANT     681    681       Q -> H. {ECO:0000269|PubMed:10329007}.
FT                                /FTId=VAR_009396.
FT   MUTAGEN     188    188       K->R: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:23665168}.
FT   MUTAGEN     321    321       Y->F: Mildly reduces kinase activity.
FT                                Does not abolish autophosphorylation on
FT                                tyrosine residues.
FT                                {ECO:0000269|PubMed:23665168}.
FT   CONFLICT     32     32       G -> A (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   CONFLICT     47     47       N -> S (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   CONFLICT     57     57       S -> P (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   CONFLICT    123    123       Q -> R (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   CONFLICT    266    266       A -> V (in Ref. 6; CAA05059).
FT                                {ECO:0000305}.
FT   CONFLICT    357    357       G -> R (in Ref. 6; CAA05059).
FT                                {ECO:0000305}.
FT   CONFLICT    397    397       K -> N (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   CONFLICT    592    592       A -> G (in Ref. 1; AAC50939).
FT                                {ECO:0000305}.
FT   HELIX       137    139       {ECO:0000244|PDB:4YLK}.
FT   TURN        156    158       {ECO:0000244|PDB:4YLK}.
FT   STRAND      159    168       {ECO:0000244|PDB:4YLK}.
FT   STRAND      171    178       {ECO:0000244|PDB:4YLK}.
FT   TURN        179    182       {ECO:0000244|PDB:4YLK}.
FT   STRAND      183    190       {ECO:0000244|PDB:4YLK}.
FT   HELIX       194    212       {ECO:0000244|PDB:4YLK}.
FT   TURN        214    217       {ECO:0000244|PDB:4YU2}.
FT   STRAND      219    221       {ECO:0000244|PDB:4YLK}.
FT   STRAND      224    230       {ECO:0000244|PDB:4YLK}.
FT   STRAND      233    239       {ECO:0000244|PDB:4YLK}.
FT   HELIX       245    251       {ECO:0000244|PDB:4YLK}.
FT   TURN        252    254       {ECO:0000244|PDB:4YLK}.
FT   HELIX       259    276       {ECO:0000244|PDB:4YLK}.
FT   TURN        279    281       {ECO:0000244|PDB:4YLK}.
FT   HELIX       290    292       {ECO:0000244|PDB:4YLK}.
FT   STRAND      293    297       {ECO:0000244|PDB:4YLK}.
FT   STRAND      303    305       {ECO:0000244|PDB:4YLK}.
FT   HELIX       308    310       {ECO:0000244|PDB:2WO6}.
FT   HELIX       314    316       {ECO:0000244|PDB:4YLK}.
FT   HELIX       325    327       {ECO:0000244|PDB:4YLK}.
FT   HELIX       330    333       {ECO:0000244|PDB:4YLK}.
FT   HELIX       341    356       {ECO:0000244|PDB:4YLK}.
FT   HELIX       366    377       {ECO:0000244|PDB:4YLK}.
FT   HELIX       382    385       {ECO:0000244|PDB:4YLK}.
FT   HELIX       391    394       {ECO:0000244|PDB:4YLK}.
FT   STRAND      395    397       {ECO:0000244|PDB:4YLK}.
FT   STRAND      403    405       {ECO:0000244|PDB:4YLK}.
FT   HELIX       423    426       {ECO:0000244|PDB:4YLK}.
FT   TURN        427    432       {ECO:0000244|PDB:4YLK}.
FT   HELIX       434    436       {ECO:0000244|PDB:4YLK}.
FT   TURN        437    440       {ECO:0000244|PDB:4YLK}.
FT   HELIX       446    459       {ECO:0000244|PDB:4YLK}.
FT   TURN        464    466       {ECO:0000244|PDB:4YLK}.
FT   HELIX       470    475       {ECO:0000244|PDB:4YLK}.
FT   HELIX       477    479       {ECO:0000244|PDB:4YLK}.
SQ   SEQUENCE   763 AA;  85584 MW;  7C3A52A3CBB04FB5 CRC64;
     MHTGGETSAC KPSSVRLAPS FSFHAAGLQM AGQMPHSHQY SDRRQPNISD QQVSALSYSD
     QIQQPLTNQV MPDIVMLQRR MPQTFRDPAT APLRKLSVDL IKTYKHINEV YYAKKKRRHQ
     QGQGDDSSHK KERKVYNDGY DDDNYDYIVK NGEKWMDRYE IDSLIGKGSF GQVVKAYDRV
     EQEWVAIKII KNKKAFLNQA QIEVRLLELM NKHDTEMKYY IVHLKRHFMF RNHLCLVFEM
     LSYNLYDLLR NTNFRGVSLN LTRKFAQQMC TALLFLATPE LSIIHCDLKP ENILLCNPKR
     SAIKIVDFGS SCQLGQRIYQ YIQSRFYRSP EVLLGMPYDL AIDMWSLGCI LVEMHTGEPL
     FSGANEVDQM NKIVEVLGIP PAHILDQAPK ARKFFEKLPD GTWNLKKTKD GKREYKPPGT
     RKLHNILGVE TGGPGGRRAG ESGHTVADYL KFKDLILRML DYDPKTRIQP YYALQHSFFK
     KTADEGTNTS NSVSTSPAME QSQSSGTTSS TSSSSGGSSG TSNSGRARSD PTHQHRHSGG
     HFTAAVQAMD CETHSPQVRQ QFPAPLGWSG TEAPTQVTVE THPVQETTFH VAPQQNALHH
     HHGNSSHHHH HHHHHHHHHG QQALGNRTRP RVYNSPTNSS STQDSMEVGH SHHSMTSLSS
     STTSSSTSSS STGNQGNQAY QNRPVAANTL DFGQNGAMDV NLTVYSNPRQ ETGIAGHPTY
     QFSANTGPAH YMTEGHLTMR QGADREESPM TGVCVQQSPV ASS
//
